Alendronate (Fosamax) reduces fracture rates among women with osteoporosis, usually defined as bone mineral density T-scores lower than -2.5. However, the benefit of alendronate in women with ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

Alendronate is superior to alfacalcidol for prevention of glucocorticoid-associated bone loss in patients with ulcerative colitis, report Mitsuyama and colleagues. Bone loss is common in patients ...

Alendronate sodium is a bisphosphonate used to treat Paget disease of bone (PDB). The approved dosage of 40 mg/day for 6 months is generally well tolerated, but esophageal irritation can occur if ...